Is Sensei Biotherapeutics Stock a Good Investment?
Sensei Biotherapeutics Investment Advice | SNSE |
- Examine Sensei Biotherapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Sensei Biotherapeutics' leadership team and their track record. Good management can help Sensei Biotherapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Sensei Biotherapeutics' business and its evolving consumer preferences.
- Compare Sensei Biotherapeutics' performance and market position to its competitors. Analyze how Sensei Biotherapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Sensei Biotherapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Sensei Biotherapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Sensei Biotherapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Sensei Biotherapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Sensei Biotherapeutics Stock
Researching Sensei Biotherapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 34.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.31. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sensei Biotherapeutics recorded a loss per share of 1.19. The entity had not issued any dividends in recent years.
To determine if Sensei Biotherapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sensei Biotherapeutics' research are outlined below:
| Sensei Biotherapeutics is way too risky over 90 days horizon | |
| Sensei Biotherapeutics has some characteristics of a very speculative penny stock | |
| Sensei Biotherapeutics appears to be risky and price may revert if volatility continues | |
| Sensei Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (34.1 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Sensei Biotherapeutics currently holds about 123.71 M in cash with (32.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.03, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Sensei Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 34.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: Sensei Biotherapeutics to Participate in Citis 2024 Global Healthcare Conference |
Sensei Biotherapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sensei Biotherapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sensei Biotherapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Sensei Biotherapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Sensei Biotherapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-08-04 | 2021-06-30 | -0.29 | -0.32 | -0.03 | 10 | ||
2024-05-09 | 2024-03-31 | -0.28 | -0.32 | -0.04 | 14 | ||
2022-03-10 | 2021-12-31 | -0.34 | -0.3 | 0.04 | 11 | ||
2022-08-09 | 2022-06-30 | -0.39 | -0.34 | 0.05 | 12 | ||
2022-05-10 | 2022-03-31 | -0.35 | -0.4 | -0.05 | 14 | ||
2023-11-07 | 2023-09-30 | -0.34 | -0.28 | 0.06 | 17 | ||
2022-11-08 | 2022-09-30 | -0.37 | -0.44 | -0.07 | 18 | ||
2021-11-09 | 2021-09-30 | -0.24 | -0.32 | -0.08 | 33 |
Know Sensei Biotherapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sensei Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sensei Biotherapeutics backward and forwards among themselves. Sensei Biotherapeutics' institutional investor refers to the entity that pools money to purchase Sensei Biotherapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Cresset Asset Management, Llc | 2024-09-30 | 19.7 K | Two Sigma Securities, Llc | 2024-06-30 | 18.6 K | Xtx Topco Ltd | 2024-09-30 | 13.9 K | Deuterium Capital Management, Llc | 2024-06-30 | 11 K | Blackrock Inc | 2024-06-30 | 7.8 K | Tower Research Capital Llc | 2024-06-30 | 7.1 K | Jpmorgan Chase & Co | 2024-06-30 | 748 | Royal Bank Of Canada | 2024-06-30 | 247 | Bank Of America Corp | 2024-06-30 | 139 | Ikarian Capital, Llc | 2024-09-30 | 650 K | Vanguard Group Inc | 2024-09-30 | 618.8 K |
Sensei Biotherapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.97 M.Market Cap |
|
Sensei Biotherapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.46) | (0.48) | |
| Return On Capital Employed | (0.54) | (0.51) | |
| Return On Assets | (0.46) | (0.48) | |
| Return On Equity | (0.53) | (0.50) |
Determining Sensei Biotherapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Sensei Biotherapeutics is a good buy. For example, gross profit margin measures Sensei Biotherapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sensei Biotherapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Sensei Biotherapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sensei Biotherapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Sensei Biotherapeutics' management manipulating its earnings.
Evaluate Sensei Biotherapeutics' management efficiency
Sensei Biotherapeutics has return on total asset (ROA) of (0.2703) % which means that it has lost $0.2703 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4517) %, meaning that it created substantial loss on money invested by shareholders. Sensei Biotherapeutics' management efficiency ratios could be used to measure how well Sensei Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.48. The current year's Return On Capital Employed is expected to grow to -0.51. At present, Sensei Biotherapeutics' Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.32 | 2.44 | |
| Tangible Book Value Per Share | 2.32 | 2.44 | |
| Enterprise Value Over EBITDA | (0.38) | (0.39) | |
| Price Book Value Ratio | 0.30 | 0.31 | |
| Enterprise Value Multiple | (0.38) | (0.39) | |
| Price Fair Value | 0.30 | 0.31 | |
| Enterprise Value | 41.4 M | 39.3 M |
Leadership at Sensei Biotherapeutics emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta 0.059 |
Basic technical analysis of Sensei Stock
As of the 29th of November, Sensei Biotherapeutics has the Coefficient Of Variation of 2607.38, risk adjusted performance of 0.0388, and Semi Deviation of 7.8. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sensei Biotherapeutics, as well as the relationship between them. Please validate Sensei Biotherapeutics variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Sensei Biotherapeutics is priced more or less accurately, providing market reflects its prevalent price of 0.56 per share. As Sensei Biotherapeutics is a penny stock we also advise to double-check its total risk alpha numbers.Sensei Biotherapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sensei Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sensei Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sensei Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sensei Biotherapeutics' Outstanding Corporate Bonds
Sensei Biotherapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sensei Biotherapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Sensei bonds can be classified according to their maturity, which is the date when Sensei Biotherapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| SENMED 2927 01 NOV 51 Corp BondUS81728XAA63 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| ST 5875 01 SEP 30 Corp BondUS81725WAL72 | View | |
| US81725WAK99 Corp BondUS81725WAK99 | View |
Understand Sensei Biotherapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Sensei Biotherapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0388 | |||
| Market Risk Adjusted Performance | (0.64) | |||
| Mean Deviation | 6.98 | |||
| Semi Deviation | 7.8 | |||
| Downside Deviation | 8.85 | |||
| Coefficient Of Variation | 2607.38 | |||
| Standard Deviation | 13.33 | |||
| Variance | 177.7 | |||
| Information Ratio | 0.0289 | |||
| Jensen Alpha | 0.59 | |||
| Total Risk Alpha | (1.51) | |||
| Sortino Ratio | 0.0436 | |||
| Treynor Ratio | (0.65) | |||
| Maximum Drawdown | 110.76 | |||
| Value At Risk | (13.21) | |||
| Potential Upside | 10.2 | |||
| Downside Variance | 78.3 | |||
| Semi Variance | 60.85 | |||
| Expected Short fall | (8.74) | |||
| Skewness | 4.66 | |||
| Kurtosis | 31.86 |
| Risk Adjusted Performance | 0.0388 | |||
| Market Risk Adjusted Performance | (0.64) | |||
| Mean Deviation | 6.98 | |||
| Semi Deviation | 7.8 | |||
| Downside Deviation | 8.85 | |||
| Coefficient Of Variation | 2607.38 | |||
| Standard Deviation | 13.33 | |||
| Variance | 177.7 | |||
| Information Ratio | 0.0289 | |||
| Jensen Alpha | 0.59 | |||
| Total Risk Alpha | (1.51) | |||
| Sortino Ratio | 0.0436 | |||
| Treynor Ratio | (0.65) | |||
| Maximum Drawdown | 110.76 | |||
| Value At Risk | (13.21) | |||
| Potential Upside | 10.2 | |||
| Downside Variance | 78.3 | |||
| Semi Variance | 60.85 | |||
| Expected Short fall | (8.74) | |||
| Skewness | 4.66 | |||
| Kurtosis | 31.86 |
Consider Sensei Biotherapeutics' intraday indicators
Sensei Biotherapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Sensei Biotherapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Sensei Biotherapeutics time-series forecasting models is one of many Sensei Biotherapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Sensei Biotherapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Sensei Stock media impact
Far too much social signal, news, headlines, and media speculation about Sensei Biotherapeutics that are available to investors today. That information is available publicly through Sensei media outlets and privately through word of mouth or via Sensei internal channels. However, regardless of the origin, that massive amount of Sensei data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Sensei Biotherapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Sensei Biotherapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Sensei Biotherapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Sensei Biotherapeutics alpha.
Sensei Biotherapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Sensei Biotherapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Sensei Biotherapeutics Corporate Management
| Edward Horst | Chief Officer | Profile | |
| Christopher JD | VP Counsel | Profile | |
| Elisabeth Colunio | VP HR | Profile | |
| Lora Pike | Vice Communications | Profile | |
| Steven Fuller | Chief Officer | Profile | |
| Robert MD | Chief Officer | Profile | |
| Erin Colgan | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sensei Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Sensei Stock refer to our How to Trade Sensei Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sensei Biotherapeutics. If investors know Sensei will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sensei Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.19) | Return On Assets (0.27) | Return On Equity (0.45) |
The market value of Sensei Biotherapeutics is measured differently than its book value, which is the value of Sensei that is recorded on the company's balance sheet. Investors also form their own opinion of Sensei Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sensei Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sensei Biotherapeutics' market value can be influenced by many factors that don't directly affect Sensei Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Sensei Biotherapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Sensei Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sensei Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.